Models used to screen for the treatment of multidrug resistant cancer facilitated by transporter-based efflux

Aberuyi N, Rahgozar S, Khosravi DZ, Moafi A, Masotti A, Paolini A (2017) The translational expression of ABCA2 and ABCA3 is a strong prognostic biomarker for multidrug resistance in pediatric acute lymphoblastic leukemia. Onco Targets Ther 10:3373–3380. https://doi.org/10.2147/OTT.S140488 CrossRefPubMedPubMedCentral

Akasov R, Drozdova M, Zaytseva-Zotova D, Leko M, Chelushkin P, Marc A, Chevalot I, Burov S, Klyachko N, Vandamme T (2017) Novel doxorubicin derivatives: synthesis and cytotoxicity study in 2D and 3D in vitro models. Adv Pharm Bull 7:593–601. https://doi.org/10.15171/apb.2017.071 CrossRefPubMedPubMedCentral

Alonso-Nocelo M, Abuin C, Lopez-Lopez R, De la Fuente M (2016) Development and characterization of a three-dimensional co-culture model of tumor T cell infiltration. Biofabrication 8:025002. https://doi.org/10.1088/1758-5090/8/2/025002 CrossRefPubMed

Ambrogio C, Carmona FJ, Vidal A, Falcone M, Nieto P, Romero OA, Puertas S, Vizoso M, Nadal E, Poggio T, Sánchez-Céspedes M, Esteller M, Mulero F, Voena C, Chiarle R, Barbacid M, Santamaria D, Villanueva A (2014) Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts. Cancer Res 74:5978–5988. https://doi.org/10.1158/0008-5472.CAN-14-1606 CrossRefPubMed

Antoni D, Burckel H, Josset E, Noel G (2015) Three-dimensional cell culture: a breakthrough in vivo. Int J Mol Sci 16:5517–5527. https://doi.org/10.3390/ijms16035517 CrossRefPubMedPubMedCentral

Argov M, Kashi R, Peer D, Margalit R (2009) Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen. Cancer Lett 274:118–125. https://doi.org/10.1016/j.canlet.2008.09.005 CrossRefPubMed

Arnaud O, Boumendjel A, Geze A, Honorat M, Matera EL, Guitton J, Stein WD, Bates SE, Falson P, Dumontet C, Di Pietro A, Payen L (2011) The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan. Eur J Cancer 47:640–648. https://doi.org/10.1016/j.ejca.2010.11.019 CrossRefPubMedPubMedCentral

Arvelo F, Poupon MF, Bichat F, Grossin F, Bourgeois Y, Jacrot M, Bastian G, Le Chevalier T (1995) Adding a reverser (Verapamil) to combined chemotherapy overrides resistance in small cell lung cancer xenografts. Eur J Cancer 31A:1862–1868. https://doi.org/10.1016/0959-8049(95)00386-W CrossRefPubMed

Ashraf SQ, Nicholls AM, Wilding JL, Ntouroupi TG, Mortensen NJ, Bodmer WF (2012) Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel. PNAS 109:21046–21051. https://doi.org/10.1073/pnas.1218750110 CrossRefPubMedPubMedCentral

Bachmann AS, Opoku-Ansah J, Ibarra-Rivera TR, Yco LP, Ambadi S, Roberts CC, Chang CE, Pirrung MC (2016) Syrbactin structural analog TIR-199 blocks proteasome activity and induces tumor cell death. J Biol Chem 291:8350–8362. https://doi.org/10.1074/jbc.M115.710053 CrossRefPubMedPubMedCentral

Balaji SA, Udupa N, Chamallamudi MR, Gupta V, Rangarajan A (2016) Role of the drug transporter ABCC3 in breast cancer chemoresistance. PLoS One 11:e0155013. https://doi.org/10.1371/journal.pone.0155013 CrossRefPubMedPubMedCentral

Barrera-Rodríguez R, Fuentes JM (2015) Multidrug resistance characterization in multicellular tumour spheroids from two human lung cancer cell lines. Cancer Cell Int 15:47. https://doi.org/10.1186/s12935-015-0200-6 CrossRefPubMedPubMedCentral

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jané-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P Jr, De Silva M, Jagtap K, Jones MD, Wang L, Hatton C, Palescandolo E, Gupta S, Mahan S, Sougnez C, Onofrio RC, Liefeld T, MacConaill L, Winckler W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G, Ardlie K, Chan V, Myer VE, Weber BL, Porter J, Warmuth M, Finan P, Harris JL, Meyerson M, Golub TR, Morrissey MP, Sellers WR, Schlegel R, Garraway LA (2012) The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603–607. https://doi.org/10.1038/nature11003 CrossRefPubMedPubMedCentral

Bartholomae S, Gruhn B, Debatin KM, Zimmermann M, Creutzig U, Reinhardt D, Steinbach D (2016) Coexpression of multiple ABC-transporters is strongly associated with treatment response in childhood acute myeloid leukemia. Pediatr Blood Cancer 63:242–247. https://doi.org/10.1002/pbc.25785 CrossRefPubMed

Bebawy M, Combes V, Lee E, Jaiswal R, Gong J, Bonhoure A, Grau GE (2009) Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells. Leukemia 23:1643–1649. https://doi.org/10.1038/leu.2009.76 CrossRefPubMed

Bhise NS, Ribas J, Manoharan V, Zhang YS, Polini A, Massa S, Dokmeci MR, Khademhosseini A (2014) Organ-on-a-chip platforms for studying drug delivery systems. J Control Release 190:82–93. https://doi.org/10.1016/j.jconrel.2014.05.004 CrossRefPubMedPubMedCentral

Biedler JL, Riehm H (1970) Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 30:1174–1184PubMed

Bradshaw-Pierce EL, Pitts TM, Tan AC, McPhillips K, West M, Gustafson DL, Halsey C, Nguyen L, Lee NV, Kan JL, Murray BW, Eckhardt SG (2013) Tumor P-glycoprotein correlates with efficacy of PF-3758309 in in vitro and in vivo models of colorectal cancer. Front Pharmacol 4:22. https://doi.org/10.3389/fphar.2013.00022 CrossRefPubMedPubMedCentral

Breslin S, O’Driscoll L (2013) Three-dimensional cell culture: the missing link in drug discovery. Drug Discov Today 18:240–249. https://doi.org/10.1016/j.drudis.2012.10.003 CrossRefPubMed

Breslin S, O’Driscoll L (2016) The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance. Oncotarget 7:45745–45756. https://doi.org/10.18632/oncotarget.9935 CrossRefPubMedPubMedCentral

Bressy C, Hastie E, Grdzelishvili VZ (2017) Combining oncolytic virotherapy with p53 tumor suppressor gene therapy. Mol Ther Oncolytics 5:20–40. https://doi.org/10.1016/j.omto.2017.03.002 CrossRefPubMedPubMedCentral

Brooks TA, Kennedy DR, Gruol DJ, Ojima I, Baer MR, Bernacki RJ (2004) Structure-activity analysis of taxane-based broad-spectrum multidrug resistance modulators. Anticancer Res 24:409–416PubMed

Calitz C, Hamman JH, Fey SJ, Wrzesinski K, Gouws C (2018) Recent advances in three-dimensional cell culturing to asses liver function and dysfunction: from a drug biotransformation and toxicity perspective. Toxicol Mech Methods 28:369–385. https://doi.org/10.1080/15376516.2017.1422580 CrossRefPubMed

Callaghan R, Luk F, Bebawy M (2014) Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy? Drug Metab Dispos 42:623–631. https://doi.org/10.1124/dmd.113.056176 CrossRefPubMedPubMedCentral

Caplin JD, Granados NG, James MR, Montazami R, Hashemi N (2015) Microfluidic organ-on-a-chip technology for advancement of drug development and toxicology. Adv Healthc Mater 4:1426–1450. https://doi.org/10.1002/adhm.201500040 CrossRefPubMed

Cayrefourcq L, Mazard T, Joosse S, Solassol J, Ramos J, Assenat E, Schumacher U, Costes V, Maudelonde T, Pantel K, Alix-Panabières C (2015) Establishment and characterization of a cell line from human circulating colon cancer cells. Cancer Res 75:892–901. https://doi.org/10.1158/0008-5472.CAN-14-2613 CrossRefPubMed

Cekanova M, Rathore K (2014) Animal models and therapeutic molecular targets of cancer: utility and limitations. Drug Des Dev Ther 8:1911–1921. https://doi.org/10.2147/DDDT.S49584 CrossRef

Chakravarty G, Mathur A, Mallade P, Gerlach S, Willis J, Datta A, Srivastav S, Abdel-Mageed AB, Mondal D (2016) Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells. Biochimie 124:53–64. https://doi.org/10.1016/j.biochi.2016.01.014 CrossRefPubMed

Chatzinikolaidou M (2016) Cell spheroids: the new frontiers in in vitro models for cancer drug validation. Drug Discov Today 21:1553–1560. https://doi.org/10.1016/j.drudis.2016.06.024 CrossRefPubMed

Chen S, Jiao J-W, Sun K-X, Zong Z-H, Zhao Y (2015) MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs. Drug Des Dev Ther 9:5225–5235. https://doi.org/10.2147/DDDT.S87526 CrossRef

Chen F-Y, Zhang Y, Chen X-Y, Li J-Q, Xiao X-P, Yu L-L, Tang Q (2017a) Development of a hybrid paclitaxel-loaded arsenite nanoparticle (HPAN) delivery system for synergistic combined therapy of paclitaxel-resistant cancer. J Nanopart Res 19:155. https://doi.org/10.1007/s11051-017-3848-0 CrossRef

Chen Q, Xu M, Zheng W, Xu T, Deng H, Liu J (2017b) Se/Ru-decorated porous metal-organic framework nanoparticles for the delivery of pooled siRNAs to reversing multidrug resistance in taxol-resistant breast cancer cells. ACS Appl Mater Interfaces 9:6712–6724. https://doi.org/10.1021/acsami.6b12792 CrossRefPubMed

Chen YL, Chang MC, Cheng WF (2017c) Metronomic chemotherapy and immunotherapy in cancer treatment. Cancer Lett 400:282–292. https://doi.org/10.1016/j.canlet.2017.01.040 CrossRefPubMed

Cheon DJ, Orsulic S (2011) Mouse models of cancer. Annu Rev Pathol 6:95–119. https://doi.org/10.1146/annurev.pathol.3.121806.154244 CrossRefPubMed

Clarke CJ, Holyoake TL (2017) Preclinical approaches in chronic myeloid leukemia: from cells to systems. Exp Hematol 47:13–23. https://doi.org/10.1016/j.exphem.2016.11.005 CrossRefPubMedPubMedCentral

Colabufo NA, Berardi F, Perrone R, Rapposelli S, Digiacomo M, Vanni M, Balsamo A (2008) Synthesis and biological evaluation of (hetero)arylmethyloxy- and arylmethylamine-phenyl derivatives as potent P-glycoprotein modulating agents. J Med Chem 51:1415–1422. https://doi.org/10.1021/jm701267q CrossRefPubMed

Corcoran C, Rani S, O’Brien K, O’Neill A, Prencipe M, Sheikh R, Webb G, McDermott R, Watson W, Crown J, O’Driscoll L (2012) Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PLoS One 7:e50999. https://doi.org/10.1371/journal.pone.0050999 CrossRefPubMedPubMedCentral

Curran S, Achilli T-M, Leary E, Wilks BT, Vantangoli MM, Boekelheide K, Morgan JR (2015) A 3D spheroid system to evaluate inhibitors of the ABCG2 transporter in drug uptake and penetration. Technology 3:54–63. https://doi.org/10.1142/S2339547815500028 CrossRef

Decker S, Hollingshead M, Bonomi CA, Carter JP, Sausville EA (2004) The hollow fibre model in cancer drug screening: the NCI experience. Eur J Cancer 40:821–826. https://doi.org/10.1016/j.ejca.2003.11.029 CrossRefPubMed

DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R, Matsen C, Milash BA, Nelson E, Neumayer L, Randall RL, Stijleman IJ, Welm BE, Welm AL (2011) Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 17:1514–1520. https://doi.org/10.1038/nm.2454 CrossRefPubMedPubMedCentral

Desoize B, Jardillier J-C (2000) Multicellular resistance: a paradigm for clinical resistance? Crit Rev Oncol Hematol 36:193–207. https://doi.org/10.1016/S1040-8428(00)00086-X CrossRefPubMed

Dey N, Sun Y, Leyland-Jones B, De P (2013) Evolution of tumor model: from animal model of tumor to tumor model in animal. J Cancer Ther 4:1411–1425. https://doi.org/10.4236/jct.2013.49168 CrossRef

Ding Y, Yu AQ, Li CL, Fang J, Zeng Y, Li DS (2014) TALEN-mediated Nanog disruption results in less invasiveness, more chemosensitivity and reversal of EMT in Hela cells. Oncotarget 5:8393–8401. https://doi.org/10.18632/oncotarget.2298 CrossRefPubMedPubMedCentral

Ding Y, Liu W, Yu W, Lu S, Liu M, Kaplan DL, Wang X (2018) Three-dimensional tissue culture model of human breast cancer for the evaluation of multidrug resistance. J Tissue Eng Regen Med 12:1959–1971. https://doi.org/10.1002/term.2729 CrossRefPubMed

Dipersio LP (1981) Regional growth differences of human tumour xenografts in nude mice. Lab Anim 15:179–180. https://doi.org/10.1258/002367781780959044 CrossRefPubMed

Dittrich PS, Manz A (2006) Lab-on-a-chip: microfluidics in drug discovery. Nat Rev Drug Discov 5:210–218. https://doi.org/10.1038/nrd1985 CrossRefPubMed

Dranoff G (2012) Experimental mouse tumour models: what can be learnt about human cancer immunology? Nat Rev Immunol 12:61–66. https://doi.org/10.1038/nri3129 CrossRef

Du G, Fang Q, den Toonder JM (2016) Microfluidics for cell-based high throughput screening platforms—a review. Anal Chim Acta 903:36–50. https://doi.org/10.1016/j.aca.2015.11.023 CrossRefPubMed

Edmondson R, Adcock AF, Yang L (2016) Influence of matrices on 3D-cultured prostate cancer cells’ drug response and expression of drug-action associated proteins. PLoS One 11:e0158116. https://doi.org/10.1371/journal.pone.0158116 CrossRefPubMedPubMedCentral

Efferth T, Gillet JP, Sauerbrey A, Zintl F, Bertholet V, de Longueville F, Remacle J, Steinbach D (2006) Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia. Mol Cancer Ther 5:1986–1994. https://doi.org/10.1158/1535-7163.MCT-06-0086 CrossRefPubMed

El-Ali J, Sorger PK, Jensen KF (2006) Cells on chips. Nature 442:403–411. https://doi.org/10.1038/nature05063 CrossRefPubMed

Elliott NT, Yuan F (2011) A review of three-dimensional in vitro tissue models for drug discovery and transport studies. J Pharm Sci 100:59–74. https://doi.org/10.1002/jps.22257 CrossRefPubMed

FDA (U.S. Food and Drug Administration) (2008) FDA and Clinical Drug Trials: A Short History. In: Davies M, Kerimani F (eds) A Quick Guide to Clinical Trials. Bioplan Inc., Washington, pp. 25–55

Fey SJ, Wrzesinski K (2012) Determination of drug toxicity using 3D spheroids constructed from an immortal human hepatocyte cell line. Toxicol Sci 127:403–411. https://doi.org/10.1093/toxsci/kfs122 CrossRefPubMedPubMedCentral

Fic M, Gomulkiewicz A, Grzegrzolka J, Podhorska-Okolow M, Zabel M, Dziegiel P, Jablonska K (2017) The impact of melatonin on colon cancer cells’ resistance to doxorubicin in an in vitro study. Int J Mol Sci 18:1396. https://doi.org/10.3390/ijms18071396 CrossRefPubMedCentral

Fiebig H-H, Burger AM (2002) Human tumor xenografts and explants. Humana Press Inc, Totowa

Fiori ME, Villanova L, De Maria R (2017) Cancer stem cells: at the forefront of personalized medicine and immunotherapy. Curr Opin Pharmacol 35:1–11. https://doi.org/10.1016/j.coph.2017.04.006 CrossRefPubMed

Flens MJ, Zaman GJR, Van der Valk P, Izquierdo MA, Schroeijers AB, Scheffer GL, Van der Groep P, De Haas M, Meijer CJLM, Scheper RJ (1996) Tissue distribution of the multidrug resistance protein. Am J Pathol 148:1237–1247PubMedPubMedCentral

Fogh J, Fogh JM, Orfeo T (1977) One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 59:221–226. https://doi.org/10.1093/jnci/59.1.221 CrossRefPubMed

Frese KK, Tuveson DA (2007) Maximizing mouse cancer models. Nat Rev Cancer 7:645–658. https://doi.org/10.1038/nrc2192 CrossRefPubMed

Fu X-T, Song K, Zhou J, Shi Y-H, Liu W-R, Shi G-M, Gao Q, Wang X-Y, Ding Z-B, Fan J (2019) Tumor-associated macrophages modulate resistance to oxaliplatin via inducing autophagy in hepatocellular carcinoma. Cancer Cell Int 19:71. https://doi.org/10.1186/s12935-019-0771-8 CrossRefPubMedPubMedCentral

Gangloff A, Hsueh W-A, Kesner AL, Kiesewetter DO, Pio BS, Pegram MD, Beryt M, Townsend A, Czernin J, Phelps ME, Silverman DHS (2005) Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with 18F-Fluoropaclitaxel. J Nucl Med 46:1866–1871PubMed

Gao H, Korn JM, Ferretti S, Monahan JE, Wang Y, Singh M, Zhang C, Schnell C, Yang G, Zhang Y, Balbin OA, Barbe S, Cai H, Casey F, Chatterjee S, Chiang DY, Chuai S, Cogan SM, Collins SD, Dammassa E, Ebel N, Embry M, Green J, Kauffmann A, Kowal C, Leary RJ, Lehar J, Liang Y, Loo A, Lorenzana E, Robert McDonald E 3rd, McLaughlin ME, Merkin J, Meyer R, Naylor TL, Patawaran M, Reddy A, Roelli C, Ruddy DA, Salangsang F, Santacroce F, Singh AP, Tang Y, Tinetto W, Tobler S, Velazquez R, Venkatesan K, Von Arx F, Wang HQ, Wang Z, Wiesmann M, Wyss D, Xu F, Bitter H, Atadja P, Lees E, Hofmann F, Li E, Keen N, Cozens R, Jensen MR, Pryer NK, Williams JA, Sellers WR (2015) High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med 21:1318–1325. https://doi.org/10.1038/nm.3954 CrossRefPubMed

Gayathri L, Karthikeyan BS, Rajalakshmi M, Dhanasekaran D, Li AP, Akbarsha MA (2018) Metabolism-dependent cytotoxicity of citrinin and ochratoxin A alone and in combination as assessed adopting integrated discrete multiple organ co-culture (IdMOC). Toxicol In Vitro 46:166–177. https://doi.org/10.1016/j.tiv.2017.09.022 CrossRefPubMed

Ghaemmaghami AM, Hancock MJ, Harrington H, Kaji H, Khademhosseini A (2012) Biomimetic tissues on a chip for drug discovery. Drug Discov Today 17:173–181. https://doi.org/10.1016/j.drudis.2011.10.029 CrossRefPubMed

Ghavami G, Kazemali M, Sardari S (2011) Informatics of drug synergism in naturally occurring anticancer agents. Recent Pat Anti-Cancer Drug Discov 6:26–44. https://doi.org/10.2174/157489211793980105 CrossRef

Goldstein LJ, Galski H, Fojo A, Willingham M, Lai S, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM, Pastan I (1989) Expression of a multidrug resistance gene in human tumors. J Natl Cancer Inst 81:116–124CrossRefPubMed

Gottesman MM, Pastan IH (2015) The role of multidrug resistance efflux pumps in cancer: revisiting a JNCI publication exploring expression of the MDR1 (P-glycoprotein) gene. J Natl Cancer Inst 107:1. https://doi.org/10.1093/jnci/djv222 CrossRef

Gould SE, Junttila MR, De Sauvage FJ (2015) Translational value of mouse models in oncology drug development. Nat Med 21:431–439. https://doi.org/10.1038/nm.3853 CrossRefPubMed

Griffith LG, Swartz MA (2006) Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol 7:211–224. https://doi.org/10.1038/nrm1858 CrossRefPubMed

Gu L, Tsark WM, Brown DA, Blanchard S, Synold TW, Kane SE (2009) A new model for studying tissue-specific mdr1a gene expression in vivo by live imaging. Proc Natl Acad Sci USA 106:5394–5399. https://doi.org/10.1073/pnas.0807343106 CrossRefPubMedPubMedCentral

Guo MT, Rotem A, Heyman JA, Weitz DA (2012) Droplet microfluidics for high-throughput biological assays. Lab Chip 12:2146–2155. https://doi.org/10.1039/c2lc21147e CrossRefPubMed

Haddad TC, Yee D (2008) Of mice and (wo)men: is this any way to test a new drug? J Clin Oncol 26:830–832. https://doi.org/10.1200/JCO.2007.14.9062 CrossRefPubMed

Hamilton G (2014) Cytotoxic effects of fascaplysin against small cell lung cancer cell lines. Mar Drugs 12:1377–1389. https://doi.org/10.3390/md12031377 CrossRefPubMedPubMedCentral

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. https://doi.org/10.1016/j.cell.2011.02.013 CrossRefPubMed

He C, Lu K, Liu D, Lin W (2014) Nanoscale metal–organic frameworks for the co-delivery of cisplatin and pooled siRNAs to enhance therapeutic efficacy in drug-resistant ovarian cancer cells. J Am Chem Soc 136:5181–5184. https://doi.org/10.1021/ja4098862 CrossRefPubMedPubMedCentral

Hembruff SL, Laberge ML, Villeneuve DJ, Guo B, Veitch Z, Cecchetto M, Parissenti AM (2008) Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance. BMC Cancer 8:318. https://doi.org/10.1186/1471-2407-8-318 CrossRefPubMedPubMedCentral

Hickman JA, Graeser R, De Hoogt R, Vidic S, Brito C, Gutekunst M, Van der Kuip H (2014) Three-dimensional models of cancer for pharmacology and cancer cell biology: capturing tumor complexity in vitro/ex vivo. Biotechnol J 9:1115–1128. https://doi.org/10.1002/biot.201300492 CrossRefPubMed

Hida K, Kikuchi H, Maishi N, Hida Y (2017) ATP-binding cassette transporters in tumor endothelial cells and resistance to metronomic chemotherapy. Cancer Lett 400:305–310. https://doi.org/10.1016/j.canlet.2017.02.006 CrossRefPubMed

Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA (2010) Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol 148:3–15. https://doi.org/10.1016/j.jbiotec.2010.01.012 CrossRefPubMed

Hollingshead MG, Alley MC, Camalier RF, Abbott BJ, Mayo JG, Malspeis L, Grever MR (1995) In vivo cultivation of tumor cells in hollow fibers. Life Sci 57:131–141. https://doi.org/10.1016/0024-3205(95)00254-4 CrossRefPubMed

Hughes P, Marshall D, Reid Y, Parkes H, Gelber C (2007) The cost of using unauthenticated, over-passaged cell lines: how much more data do we need? Biotechniques 43:575–584. https://doi.org/10.2144/000112598 CrossRefPubMed

Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Hsin HY, Ingber DE (2010) Reconstituting organ-level lung functions on a chip. Science 328:1662–1668. https://doi.org/10.1126/science.1188302 CrossRefPubMedPubMedCentral

Husaini R, Ahmad M, Zakaria Z (2017) Effectiveness of imatinib mesylate over etoposide in the treatment of sensitive and resistant chronic myeloid leukaemia cells in vitro. Exp Ther Med 13:3209–3216. https://doi.org/10.3892/etm.2017.4443 CrossRefPubMedPubMedCentral

ICH (1998) General considerations for clinical trials ICH Topic E8. In: ICH Guidance for Industry: Health Canada

Imamura Y, Mukohara T, Shimono Y, Funakoshi Y, Chayahara N, Toyoda M, Kiyota N, Takao S, Kono S, Nakatsura T (2015) Comparison of 2D-and 3D-culture models as drug-testing platforms in breast cancer. Oncol Rep 33:1837–1843. https://doi.org/10.3892/or.2015.3767 CrossRefPubMed

Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M, Arbuck S, Hollingshead M, Sausville EA (2001) Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84:1424–1431. https://doi.org/10.1054/bjoc.2001.1796 CrossRefPubMedPubMedCentral

Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152–162. https://doi.org/10.1016/0005-2736(76)90160-7 CrossRefPubMed

Junttila MR, De Sauvage FJ (2013) Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501:346–354. https://doi.org/10.1038/nature12626 CrossRefPubMed

Kars MD, İșeri ÖD, Gündüz U, Ural AU, Arpaci F, Molnár J (2006) Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds. Anticancer Res 26:4559–4568PubMed

Kashaninejad N, Nikmaneshi MR, Moghadas H, Kiyoumarsi OA, Rismanian M, Barisam M, Saidi MS, Firoozabadi B (2016) Organ-tumor-on-a-chip for chemosensitivity assay: a critical review. Micromachines 7:130. https://doi.org/10.3390/mi7080130 CrossRefPubMedCentral

Katayama R, Sakashita T, Yanagitani N, Ninomiya H, Horiike A, Friboulet L, Gainor JF, Motoi N, Dobashi A, Sakata S, Tambo Y, Kitazono S, Sato S, Koike S, John Iafrate A, Mino-Kenudson M, Ishikawa Y, Shaw AT, Engelman JA, Takeuchi K, Nishio M, Fujita N (2016) P-Glycoprotein mediates Ceritinib resistance in anaplastic lymphoma kinase-rearranged non-small cell lung cancer. EBioMedicine 3:54–66. https://doi.org/10.1016/j.ebiom.2015.12.009 CrossRefPubMed

Katt ME, Placone AL, Wong AD, Xu ZS, Searson PC (2016) In vitro tumor models: advantages, disadvantages, variables, and selecting the right platform. Front Bioeng Biotechnol 4:12. https://doi.org/10.3389/fbioe.2016.00012 CrossRefPubMedPubMedCentral

Ke W, Yu P, Wang J, Wang R, Guo C, Zhou L, Li C, Li K (2011) MCF-7/ADR cells (re-designated NCI/ADR-RES) are not derived from MCF-7 breast cancer cells: a loss for breast cancer multidrug-resistant research. Med Oncol 28:S135–S141. https://doi.org/10.1007/s12032-010-9747-1 CrossRefPubMed

Killion JJ, Radinsky R, Fidler IJ (1998) Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 17:279–284. https://doi.org/10.1023/A:1006140513233 CrossRefPubMed

Kim TH, Shin YJ, Won AJ, Lee BM, Choi WS, Jung JH, Chung HY, Kim HS (2014) Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. Biochim Biophys Acta 1840:615–625. https://doi.org/10.1016/j.bbagen.2013.10.023 CrossRefPubMed

Kim MS, Haney MJ, Zhao Y, Mahajan V, Deygen I, Klyachko NL, Inskoe E, Piroyan A, Sokolsky M, Okolie O, Hingtgen SD, Kabanov AV, Batrakova EV (2016) Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine 12:655–664. https://doi.org/10.1016/j.nano.2015.10.012 CrossRefPubMed

Kleffel S, Lee N, Lezcano C, Wilson BJ, Sobolewski K, Saab KR, Mueller H, Zhan Q, Posch C, Elco CP, DoRosario A, Garcia SS, Thakuria M, Wang YE, Wang LC, Murphy GF, Frank MH, Schatton T (2016) ABCB5-targeted chemoresistance reversal inhibits merkel cell carcinoma growth. J Investig Dermatol 136:838–846. https://doi.org/10.1016/j.jid.2015.12.038 CrossRefPubMed

Krishna R, Mayer LD (2000) Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 11:265–283. https://doi.org/10.1016/S0928-0987(00)00114-7 CrossRefPubMed

Kriston-Vizi J, Flotow H (2017) Getting the whole picture: high content screening using three-dimensional cellular model systems and whole animal assays. Cytom A 91:152–159. https://doi.org/10.1002/cyto.a.22907 CrossRef

Kumar S, Bajaj S, Bodla RB (2016) Preclinical screening methods in cancer. Indian J Pharmacol 48:481–486. https://doi.org/10.4103/0253-7613.190716 CrossRefPubMedPubMedCentral

LaBarbera DV, Reid BG, Yoo BH (2012) The multicellular tumor spheroid model for high-throughput cancer drug discovery. Expert Opin Drug Discov 7:819–830. https://doi.org/10.1517/17460441.2012.708334 CrossRefPubMed

Ledford H (2016) US cancer institute overhauls cell lines. Nature 530:391. https://doi.org/10.1038/nature.2016.19364 CrossRefPubMed

Lee H (2014) Genetically engineered mouse models for drug development and preclinical trials. Biomol Ther (Seoul) 22:267–274. https://doi.org/10.4062/biomolther.2014.074 CrossRef

Lee KH, Rhee KH (2005) Correlative effect between in vivo hollow fiber assay and xenografts assay in drug screening. Cancer Res Treat 37:196–200. https://doi.org/10.4143/crt.2005.37.3.196 CrossRefPubMedPubMedCentral

Lee EY, Chang CY, Hu N, Wang YC, Lai CC, Herrup K, Lee WH, Bradley A (1992) Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359:288–294. https://doi.org/10.1038/359288a0 CrossRefPubMed

Lee J, Lilly GD, Doty RC, Podsiadlo P, Kotov NA (2009) In vitro toxicity testing of nanoparticles in 3D cell culture. Small 5:1213–1221. https://doi.org/10.1002/smll.200801788 CrossRefPubMed

Lee HS, Park SB, Kim SA, Kwon SK, Cha H, Lee DY, Ro S, Cho JM, Song SY (2017) A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance. Sci Rep 7:41615. https://doi.org/10.1038/srep41615 CrossRefPubMedPubMedCentral

Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G, Mercer KE, Zhuang Y, Panetta JC, Johnston B, Scheper RJ, Stewart CF, Schuetz JD (2004) Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 24:7612–7621. https://doi.org/10.1128/MCB.24.17.7612-7621.2004 CrossRefPubMedPubMedCentral

Legrand N, Ploss A, Balling R, Becker PD, Borsotti C, Brezillon N, DeBarry J, De Jong Y, Deng H, Di Santo JP, Eisenbarth S, Eynon E, Flavell RA, Guzman CA, Huntington ND, Kremsdorf D, Manns MP, Manz MG, Mention J-J, Ott M, Rathinam C, Rice CM, Rongvaux A, Stevens S, Spits H, Strick-Marchand H, Takizawa H, Van Lent AU, Wang C, Weijer K, Willinger T, Ziegler P (2009) Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe 6:5–9. https://doi.org/10.1016/j.chom.2009.06.006 CrossRefPubMedPubMedCentral

Li AP (2005) Preclinical in vitro screening assays for drug-like properties. Drug Discov Today Technol 2:179–185. https://doi.org/10.1016/j.ddtec.2005.05.024 CrossRefPubMed

Li AP (2008) In vitro evaluation of human xenobiotic toxicity: scientific concepts and the novel integrated discrete multiple cell co-culture (IdMOC) technology. Altex 25:43–49. https://doi.org/10.14573/altex.2008.1.43 CrossRefPubMed

Li AP (2009) The use of the integrated discrete multiple organ co-culture (IdMOC (R)) system for the evaluation of multiple organ toxicity. Altern Lab Anim 37:377–385CrossRefPubMed

Li AP, Bode C, Sakai Y (2004) A novel in vitro system, the integrated discrete multiple organ cell culture (IdMOC) system, for the evaluation of human drug toxicity: comparative cytotoxicity of tamoxifen towards normal human cells from five major organs and MCF-7 adenocarcinoma breast cancer cells. Chem Biol Interact 150:129–136. https://doi.org/10.1016/j.cbi.2004.09.010 CrossRefPubMed

Li AP, Uzgare A, Saminathan H, Doshi U (2011) Integrated discrete multiple organ co-culture (IdMOC) system for the evaluation of multiple organ drug distribution, drug metabolism, and organ specific drug toxicity. Drug metabolism reviews, vol 43. Informa Healthcare, London, pp 141–142

Li AP, Uzgare A, LaForge YS (2012) Definition of metabolism-dependent xenobiotic toxicity with co-cultures of human hepatocytes and mouse 3T3 fibroblasts in the novel integrated discrete multiple organ co-culture (IdMOC) experimental system: results with model toxicants aflatoxin B1, cyclophosphamide and tamoxifen. Chem Biol Interact 199:1–8. https://doi.org/10.1016/j.cbi.2012.05.003 CrossRefPubMed

Li X, Wang H, Wang J, Chen Y, Yin X, Shi G, Li H, Hu Z, Liang X (2016) Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation. BMC Cancer 16:578. https://doi.org/10.1186/s12885-016-2640-3 CrossRefPubMedPubMedCentral

Linzey A (2013) Why animal suffering matters: Philosophy, theology, and practical ethics. Oxford University Press, NorthantsCrossRef

Liu X, Holstege H, Van der Gulden H, Treur-Mulder M, Zevenhoven J, Velds A, Kerkhoven RM, Van Vliet MH, Wessels LF, Peterse JL, Berns A, Jonkers J (2007) Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci USA 104:12111–12116. https://doi.org/10.1073/pnas.0702969104 CrossRefPubMedPubMedCentral

Liu X, Yang Q, Zhang G, Li Y, Chen Y, Weng X, Wang Y, Wang Y, Zhu X (2014) Anti-tumor pharmacological evaluation of extracts from Stellera chamaejasme L based on hollow fiber assay. BMC Complement Altern Med 14:116. https://doi.org/10.1186/1472-6882-14-116 CrossRefPubMedPubMedCentral

Longati P, Jia X, Eimer J, Wagman A, Witt M-R, Rehnmark S, Verbeke C, Toftgård R, Löhr M, Heuchel RL (2013) 3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing. BMC Cancer 13:95. https://doi.org/10.1186/1471-2407-13-95 CrossRefPubMedPubMedCentral

Lovitt CJ, Shelper TB, Avery VM (2014) Advanced cell culture techniques for cancer drug discovery. Biology 3:345–367. https://doi.org/10.3390/biology3020345 CrossRefPubMedPubMedCentral

Luker GD, Flagg TP, Sha Q, Luker KE, Pica CM, Nichols CG, Piwnica-Worms D (2001) MDR1 P-glycoprotein reduces influx of substrates without affecting membrane potential. J Biol Chem 276:49053–49060. https://doi.org/10.1074/jbc.M105192200 CrossRefPubMed

Ma H-L, Jiang Q, Han S, Wu Y, Tomshine JC, Wang D, Gan Y, Zou G, Liang X-J (2012) Multicellular tumor spheroids as an in vivo–like tumor model for three-dimensional imaging of chemotherapeutic and nano material cellular penetration. Mol Imaging 11:487–498CrossRefPubMed

Mak IWY, Evaniew N, Ghert M (2014) Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res 6:114–118PubMedPubMedCentral

Malaney P, Nicosia SV, Dave V (2014) One mouse, one patient paradigm: new avatars of personalized cancer therapy. Cancer Lett 344:1–12. https://doi.org/10.1016/j.canlet.2013.10.010 CrossRefPubMed

Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, De Cremoux P, De Plater L, Guyader C, De Pinieux G, Judde JG, Rebucci M, Tran-Perennou C, Sastre-Garau X, Sigal-Zafrani B, Delattre O, Dieras V, Poupon MF (2007) A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 13:3989–3998. https://doi.org/10.1158/1078-0432.CCR-07-0078 CrossRefPubMed

Marchetti S, Pluim D, Beijnen JH, Mazzanti R, Van Tellingen O, Schellens JHM (2014) Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183. Investig New Drugs 32:1083–1095. https://doi.org/10.1007/s10637-014-0143-0 CrossRef

Maschmeyer I, Lorenz AK, Schimek K, Hasenberg T, Ramme AP, Hübner J, Lindner M, Drewell C, Bauer S, Thomas A (2015) A four-organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents. Lab Chip 15:2688–2699. https://doi.org/10.1039/c5lc00392j CrossRefPubMed

Mi Q, Pezzuto JM, Farnsworth NR, Wani MC, Kinghorn AD, Swanson SM (2009) Use of the in vivo hollow fiber assay in natural products anticancer drug discovery. J Nat Prod 72:573–580. https://doi.org/10.1021/np800767a CrossRefPubMedPubMedCentral

Moon S, Hasan SK, Song YS, Xu F, Keles HO, Manzur F, Mikkilineni S, Hong JW, Nagatomi J, Haeggstrom E (2009) Layer by layer three-dimensional tissue epitaxy by cell-laden hydrogel droplets. Tissue Eng Part C Methods 16:157–166. https://doi.org/10.1089/ten.TEC.2009.0179 CrossRefPubMedCentral

Morton CL, Houghton PJ (2007) Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc 2:247–250. https://doi.org/10.1038/nprot.2007.25 CrossRefPubMed

Naipal KAT, Verkaik NS, Sánchez H, Van Deurzen CHM, Den Bakker MA, Hoeijmakers JHJ, Kanaar R, Vreeswijk MPG, Jager A, Van Gent DC (2016) Tumor slice culture system to assess drug response of primary breast cancer. BMC Cancer 16:78. https://doi.org/10.1186/s12885-016-2119-2 CrossRefPubMedPubMedCentral

Nath S, Devi GR (2016) Three-dimensional culture systems in cancer research: focus on tumor spheroid model. Pharmacol Ther 163:94–108. https://doi.org/10.1016/j.pharmthera.2016.03.013 CrossRefPubMedPubMedCentral

O’Connor R, Heenan M, Connolly L, Larkin A, Clynes M (2004) Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer. Anticancer Res 24:457–464PubMed

Ozben T (2006) Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett 580:2903–2909. https://doi.org/10.1016/j.febslet.2006.02.020 CrossRefPubMed

Pajic M, Iyer JK, Kersbergen A, Van der Burg E, Nygren AO, Jonkers J, Borst P, Rottenberg S (2009) Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer. Cancer Res 69:6396–6404. https://doi.org/10.1158/0008-5472.CAN-09-0041 CrossRefPubMed

Patel A, Li T-W, Anreddy N, Wang D-S, Sodani K, Gadhia S, Kathawala R, Yang D-H, Cheng C, Chen Z-S (2017) Suppression of ABCG2 mediated MDR in vitro and in vivo by a novel inhibitor of ABCG2 drug transport. Pharmacol Res 121:184–193. https://doi.org/10.1016/j.phrs.2017.04.025 CrossRefPubMed

Patil YB, Swaminathan SK, Sadhukha T, Ma L, Panyam J (2010) The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 31:358–365. https://doi.org/10.1016/j.biomaterials.2009.09.048 CrossRefPubMed

Pedersen JM, Khan EK, Bergström CAS, Palm J, Hoogstraate J, Artursson P (2017) Substrate and method dependent inhibition of three ABC-transporters (MDR1, BCRP, and MRP2). Eur J Pharm Sci 103:70–76. https://doi.org/10.1016/j.ejps.2017.03.002 CrossRefPubMed

Phelan K, May KM (2016) Mammalian cell tissue culture techniques. Curr Protoc Pharmacol 73:12.1.1–12.1.23. https://doi.org/10.1002/cpph.1 CrossRef

Phillips RM, Pearce J, Loadman PM, Bibby MC, Cooper PA, Swaine DJ, Double JA (1998) Angiogenesis in the hollow fibre tumour model influences drug delivery to tumour cells: implications for anticancer drug screening programs. Cancer Res 58:5263–5266PubMed

Pluchino KM, Hall MD, Goldsborough AS, Callaghan R, Gottesman MM (2012) Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist Updat 15:98–105. https://doi.org/10.1016/j.drup.2012.03.002 CrossRefPubMedPubMedCentral

Qian X, Cheng YH, Mruk DD, Cheng CY (2013) Breast cancer resistance protein (Bcrp) and the testis-an unexpected turn of events. Asian J Androl 15:455–460. https://doi.org/10.1038/aja.2013.24 CrossRefPubMedPubMedCentral

Qiu W, Su GH (2013) Challenges and advances in mouse modeling for human pancreatic tumorigenesis and metastasis. Cancer Metastasis Rev 32:83–107. https://doi.org/10.1007/s10555-012-9408-2 CrossRefPubMed

Qiu L, Qiao M, Chen Q, Tian C, Long M, Wang M, Li Z, Hu W, Li G, Cheng L, Cheng L, Hu H, Zhao X, Chen D (2014) Enhanced effect of pH-sensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin. Biomaterials 35:9877–9887. https://doi.org/10.1016/j.biomaterials.2014.08.008 CrossRefPubMed

Qiu J-G, Zhang Y-J, Li Y, Zhao J-M, Zhang W-J, Jiang Q-W, Mei X-L, Xue Y-Q, Qin W-M, Yang Y, Zheng D-W, Chen Y, Wei M-N, Shi Z (2015) Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter. Oncotarget 6:15494–15509. https://doi.org/10.18632/oncotarget.3820 CrossRefPubMedPubMedCentral

Rangarajan A, Weinberg RA (2003) Comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer 3:952–959. https://doi.org/10.1038/nrc1235 CrossRefPubMed

Rao MS, Reddy JK (1980) Histogenesis of pseudoductular changes induced in the pancreas of guinea pigs treated with N-methyl-N-nitrosourea. Carcinogenesis 1:1027–1037. https://doi.org/10.1093/carcin/1.12.1027 CrossRefPubMed

Redaelli S, Perini P, Ceccon M, Piazza R, Rigolio R, Mauri M, Boschelli F, Giannoudis A, Gambacorti-Passerini C (2015) In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib. J Hematol Oncol 8:81. https://doi.org/10.1186/s13045-015-0179-4 CrossRefPubMedPubMedCentral

Reynolds DS, Tevis KM, Blessing WA, Colson YL, Zaman MH, Grinstaff MW (2017) Breast cancer spheroids reveal a differential cancer stem cell response to chemotherapeutic treatment. Sci Rep 7:10382. https://doi.org/10.1038/s41598-017-10863-4 CrossRefPubMedPubMedCentral

Richmond A, Su Y (2008) Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech 1:78–82. https://doi.org/10.1242/dmm.000976 CrossRefPubMedPubMedCentral

Riffle S, Pandey RN, Albert M, Hegde RS (2017) Linking hypoxia, DNA damage and proliferation in multicellular tumor spheroids. BMC Cancer 17:338. https://doi.org/10.1186/s12885-017-3319-0 CrossRefPubMedPubMedCentral

Rolff J, Dorn C, Merk J, Fichtner I (2009) Response of patient-derived non-small cell lung cancer xenografts to classical and targeted therapies is not related to multidrug resistance markers. J Oncol. https://doi.org/10.1155/2009/814140 CrossRefPubMedPubMedCentral

Roper J, Hung KE (2012) Priceless GEMMs: genetically engineered mouse models for colorectal cancer drug development. Trends Pharmacol Sci 33:449–455. https://doi.org/10.1016/j.tips.2012.05.001 CrossRefPubMed

Rottenberg S, Jaspers JE, Kersbergen A, Van der Burg E, Nygren AO, Zander SA, Derksen PW, De Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O’Connor MJ, Martin NM, Borst P, Jonkers J (2008) High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 105:17079–17084. https://doi.org/10.1073/pnas.0806092105 CrossRefPubMedPubMedCentral

Ruppen J, Wildhaber FD, Strub C, Hall SR, Schmid RA, Geiser T, Guenat OT (2015) Towards personalized medicine: chemosensitivity assays of patient lung cancer cell spheroids in a perfused microfluidic platform. Lab Chip 15:3076–3085. https://doi.org/10.1039/c5lc00454c CrossRefPubMed

Sampson KE, Brinker A, Pratt J, Venkatraman N, Xiao Y, Blasberg J, Steiner T, Bourner M, Thompson DC (2015) Zinc finger nuclease-mediated gene knockout results in loss of transport activity for P-glycoprotein, BCRP, and MRP2 in Caco-2 cells. Drug Metab Dispos 43:199–207. https://doi.org/10.1124/dmd.114.057216 CrossRefPubMed

Saraswathy M, Gong S (2013) Different strategies to overcome multidrug resistance in cancer. Biotechnol Adv 31:1397–1407. https://doi.org/10.1016/j.biotechadv.2013.06.004 CrossRefPubMed

Sarisozen C, Abouzeid AH, Torchilin VP (2014) The effect of co-delivery of paclitaxel and curcumin by transferrin-targeted PEG-PE-based mixed micelles on resistant ovarian cancer in 3-D spheroids and in vivo tumors. Eur J Pharm Biopharm 88:539–550. https://doi.org/10.1016/j.ejpb.2014.07.001 CrossRefPubMedPubMedCentral

Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, Chodosh LA (2007) Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 9:493–505. https://doi.org/10.1038/ncb1567 CrossRefPubMed

Saw PE, Park J-K, Jon S, Farokhzad OC (2017) A drug-delivery strategy for overcoming drug resistance in breast cancer through targeting of oncofetal fibronectin. Nanomedicine 13:713–722. https://doi.org/10.1016/j.nano.2016.10.005 CrossRefPubMed

Schuh JC (2004) Trials, tribulations, and trends in tumor modeling in mice. Toxicol Pathol 32(Suppl 1):53–66. https://doi.org/10.1080/01926230490424770 CrossRefPubMed

Schuller HM, Jorquera R, Reichert A, Castonguay A (1993) Transplacental induction of pancreas tumors in hamsters by ethanol and the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res 53:2498–2501PubMed

Shaheen S, Ahmed M, Lorenzi F, Nateri AS (2016) Spheroid-formation (Colonosphere) assay for in vitro assessment and expansion of stem cells in colon cancer. Stem Cell Rev 12:492–499. https://doi.org/10.1007/s12015-016-9664-6 CrossRefPubMedCentral

Sharpless NE, DePinho RA (2006) The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 5:741–754. https://doi.org/10.1038/nrd2110 CrossRefPubMed

Shaw TJ, Senterman MK, Dawson K, Crane CA, Vanderhyden BC (2004) Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther 10:1032–1042. https://doi.org/10.1016/j.ymthe.2004.08.013 CrossRefPubMed

Shield K, Ackland ML, Ahmed N, Rice GE (2009) Multicellular spheroids in ovarian cancer metastases: biology and pathology. Gynecol Oncol 113:143–148. https://doi.org/10.1016/j.ygyno.2008.11.032 CrossRefPubMed

Shnyder SD, Hasan J, Cooper PA, Pilarinou E, Jubb E, Jayson GC, Bibby MC (2005) Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature. Anticancer Res 25:1889–1894PubMed

Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6:813–823. https://doi.org/10.1038/nrc1951 CrossRefPubMed

Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner DL (2012) Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol 12:786–798. https://doi.org/10.1038/nri3311 CrossRefPubMedPubMedCentral

Sodani K, Patel A, Kathawala RJ, Chen Z-S (2012) Multidrug resistance associated proteins in multidrug resistance. Chin J Canc 31:58–73. https://doi.org/10.5732/cjc.011.10329 CrossRef

Srivalli KMR, Lakshmi PK (2012) Overview of P-glycoprotein inhibitors: a rational outlook. Braz J Pharm Sci 48:353–367. https://doi.org/10.1590/S1984-82502012000300002 CrossRef

Stakleff KDS, Von Gruenigen VE (2003) Rodent models for ovarian cancer research. Int J Gynecol Cancer 13:405–412. https://doi.org/10.1046/j.1525-1438.2003.13317.x CrossRefPubMed

Stankevicius V, Kunigenas L, Stankunas E, Kuodyte K, Strainiene E, Cicenas J, Samalavicius NE, Suziedelis K (2017) The expression of cancer stem cell markers in human colorectal carcinoma cells in a microenvironment dependent manner. Biochem Biophys Res Commun 484:726–733. https://doi.org/10.1016/j.bbrc.2017.01.111 CrossRefPubMed

Staudacher AH, Liapis V, Brown MP (2018) Therapeutic targeting of tumor hypoxia and necrosis with antibody α-radioconjugates. Antibody Ther 1:55–63. https://doi.org/10.1093/abt/tby010 CrossRef

Stein WD, Yang J, Bates SE, Fojo T (2008) Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. Oncologist 13:1055–1062. https://doi.org/10.1634/theoncologist.2008-0016 CrossRefPubMed

Sung JH, Esch MB, Prot J-M, Long CJ, Smith A, Hickman JJ, Shuler ML (2013) Microfabricated mammalian organ systems and their integration into models of whole animals and humans. Lab Chip 13:1201–1212. https://doi.org/10.1039/c3lc41017j CrossRefPubMedPubMedCentral

Szakacs G, Varadi A, Ozvegy-Laczka C, Sarkadi B (2008) The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today 13:379–393. https://doi.org/10.1016/j.drudis.2007.12.010 CrossRefPubMed

Tannenbaum J, Bennett BT (2015) Russell and Burch’s 3Rs then and now: the need for clarity in definition and purpose. J Am Assoc Lab Anim Sci 54:120–132PubMedPubMedCentral

Tarling EJ, De Aguiar Vallim TQ, Edwards PA (2013) Role of ABC transporters in lipid transport and human disease. Trends Endocrinol Metab 24:342–350. https://doi.org/10.1016/j.tem.2013.01.006 CrossRefPubMedPubMedCentral

Tatosian DA, Shuler ML (2009) A novel system for evaluation of drug mixtures for potential efficacy in treating multidrug resistant cancers. Biotechnol Bioeng 103:187–198. https://doi.org/10.1002/bit.22219 CrossRefPubMed

Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ, Messersmith WA, Eckhardt SG (2012) Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 9:338–350. https://doi.org/10.1038/nrclinonc.2012.61 CrossRefPubMedPubMedCentral

Thoma CR, Stroebel S, Rosch N, Calpe B, Krek W, Kelm JM (2013) A high-throughput-compatible 3D microtissue co-culture system for phenotypic RNAi screening applications. J Biomol Screen 18:1330–1337. https://doi.org/10.1177/1087057113499071 CrossRefPubMed

Tiwari AK, Sodani K, Dai CL, Abuznait AH, Singh S, Xiao ZJ, Patel A, Talele TT, Fu L, Kaddoumi A, Gallo JM, Chen ZS (2013) Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. Cancer Lett 328:307–317. https://doi.org/10.1016/j.canlet.2012.10.001 CrossRefPubMed

Tuveson DA, Jacks T (2002) Technologically advanced cancer modeling in mice. Curr Opin Genet Dev 12:105–110. https://doi.org/10.1016/S0959-437X(01)00272-6 CrossRefPubMed

Uzgare AR, Li AP (2013) New paradigm in toxicity testing: integrated discrete multiple organ co-cultures (IdMOC) for the evaluation of xenobiotic toxicity. ALTEX Proc 2:39–46

Vallo S, Köpp R, Michaelis M, Rothweiler F, Bartsch G, Brandt MP, Gust KM, Wezel F, Blaheta RA, Haferkamp A (2017) Resistance to nanoparticle albumin-bound paclitaxel is mediated by ABCB1 in urothelial cancer cells. Oncol Lett 13:4085–4092. https://doi.org/10.3892/ol.2017.5986 CrossRefPubMedPubMedCentral

Van de Steeg E, Van Esch A, Wagenaar E, Kenworthy KE, Schinkel AH (2013) Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice. Clin Cancer Res 19:821–832. https://doi.org/10.1158/1078-0432.CCR-12-2080 CrossRefPubMed

Van der Helm MW, Van der Meer AD, Eijkel JC, Van den Berg A, Segerink LI (2016) Microfluidic organ-on-chip technology for blood-brain barrier research. Tissue Barriers 4:e1142493. https://doi.org/10.1080/21688370.2016.1142493 CrossRefPubMedPubMedCentral

Van Miltenburg MH, Jonkers J (2012) Using genetically engineered mouse models to validate candidate cancer genes and test new therapeutic approaches. Curr Opin Genet Dev 22:21–27. https://doi.org/10.1016/j.gde.2012.01.004 CrossRefPubMed

Vandenhaute E, Drolez A, Sevin E, Gosselet F, Mysiorek C, Dehouck MP (2016) Adapting coculture in vitro models of the blood-brain barrier for use in cancer research: maintaining an appropriate endothelial monolayer for the assessment of transendothelial migration. Lab Investig 96:588–598. https://doi.org/10.1038/labinvest.2016.35 CrossRefPubMed

Veiga JP, Cooper PA, Pors K, Patterson LH, Bibby MC, Shnyder SD (2011) Use of the hollow fiber assay for the evaluation of DNA damaging agents. J Pharmacol Toxicol Methods 64:226–232. https://doi.org/10.1016/j.vascn.2011.04.006 CrossRefPubMed

Verjans E-T, Doijen J, Luyten W, Landuyt B, Schoofs L (2017) Three-dimensional cell culture models for anticancer drug screening: worth the effort? J Cell Physiol 2017:1–11. https://doi.org/10.1002/jcp.26052 CrossRef

Vesel M, Rapp J, Feller D, Kiss E, Jaromi L, Meggyes M, Miskei G, Duga B, Smuk G, Laszlo T, Karner I, Pongracz JE (2017) ABCB1 and ABCG2 drug transporters are differentially expressed in non-small cell lung cancers (NSCLC) and expression is modified by cisplatin treatment via altered Wnt signaling. Respir Res 18:52. https://doi.org/10.1186/s12931-017-0537-6 CrossRefPubMedPubMedCentral

Vickers PJ, Dickson RB, Shoemaker RH, Cowan KH (1988) A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. Mol Endocrinol 2:886–892. https://doi.org/10.1210/mend-2-10-886 CrossRefPubMed

Vinci M, Gowan S, Boxall F, Patterson L, Zimmermann M, Lomas C, Mendiola M, Hardisson D, Eccles SA (2012) Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol 10:29. https://doi.org/10.1186/1741-7007-10-29 CrossRefPubMedPubMedCentral

Vlaming ML, Mohrmann K, Wagenaar E, De Waart DR, Elferink RP, Lagas JS, Van Tellingen O, Vainchtein LD, Rosing H, Beijnen JH, Schellens JH, Schinkel AH (2006) Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther 318:319–327. https://doi.org/10.1124/jpet.106.101774 CrossRefPubMed

Vysotski S, Winzelberg R, Babayeva M (2016) Overcoming cancer multidrug resistance through inhibition of microparticles. Int J Adv Med Res. https://doi.org/10.5176/2345-7201_1.4.32 CrossRef

Wang GY, So P-L, Wang L, Libove E, Wang J, Epstein EHJ (2011) Establishment of murine basal cell carcinoma allografts—a potential model for preclinical drug testing and for molecular analysis. J Investig Dermatol 131:2298–2305. https://doi.org/10.1038/jid.2011.204 CrossRefPubMed

Wang J, Seebacher N, Shi H, Kan Q, Zhenfeng D (2017a) Novel strategies to prevent the development of multidrug resistance (MDR) in cancer. Oncotarget 8:84559–84571. https://doi.org/10.18632/oncotarget.19187 CrossRefPubMedPubMedCentral

Wang Y-J, Zhang Y-K, Zhang G-N, Al Rihani SB, Wei M-N, Gupta P, Zhang X-Y, Shukla S, Ambudkar SV, Kaddoumi A, Shi Z, Chen Z-S (2017b) Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: in vitro and in vivo study. Cancer Lett 396:145–154. https://doi.org/10.1016/j.canlet.2017.03.011 CrossRefPubMedPubMedCentral

Weibel DB, Whitesides GM (2006) Applications of microfluidics in chemical biology. Curr Opin Chem Biol 10:584–591. https://doi.org/10.1016/j.cbpa.2006.10.016 CrossRefPubMed

Weltin A, Slotwinski K, Kieninger J, Moser I, Jobst G, Wego M, Ehret R, Urban GA (2014) Cell culture monitoring for drug screening and cancer research: a transparent, microfluidic, multi-sensor microsystem. Lab Chip 14:138–146. https://doi.org/10.1039/c3lc50759a CrossRefPubMed

White RDV (2013) Can mouse avatars guide cancer treatment? https://www.onclive.com/publications/obtn/2013/january-2013/can-mouse-avatars-guide-cancer-treatment. Accessed 6 Mar 2019

Whitesides GM (2006) The origins and the future of microfluidics. Nature 442:368–373. https://doi.org/10.1038/nature05058 CrossRefPubMed

Whitt JD, Keeton AB, Gary BD, Sklar LA, Sodani K, Chen Z-S, Piazza GA (2016) Sulindac sulfide selectively increases sensitivity of ABCC1 expressing tumor cells to doxorubicin and glutathione depletion. J Biomed Res 30:120–133. https://doi.org/10.7555/JBR.30.20150108 CrossRefPubMed

Williams SA, Anderson WC, Santaguida MT, Dylla SJ (2013) Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century. Lab Investig 93:970–982. https://doi.org/10.1038/labinvest.2013.92 CrossRefPubMed

Winter U, Mena HA, Negrotto S, Arana E, Pascual-Pasto G, Laurent V, Sunol M, Chantada GL, Carcaboso AM, Schaiquevich P (2016) Schedule-dependent antiangiogenic and cytotoxic effects of chemotherapy on vascular endothelial and retinoblastoma cells. PLoS One 11:e0160094. https://doi.org/10.1371/journal.pone.0160094 CrossRefPubMedPubMedCentral

Wong HL, Rauth AM, Bendayan R, Manias JL, Ramaswamy M, Liu Z, Erhan SZ, Wu XY (2006) A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res 23:1574–1585. https://doi.org/10.1007/s11095-006-0282-x CrossRefPubMed

Wilding JL, McGowan S, Liu Y, Bodmer WF (2010) Replication error deficient and proficient colorectal cancer gene expression differences caused by 3'UTR polyT sequence deletions. Proc Natl Acad Sci 107(49):21058–21063. https://doi.org/10.1073/pnas.1015604107 CrossRefPubMedPubMedCentral

Wrzesinski K, Fey SJ (2013) After trypsinisation, 3D spheroids of C3A hepatocytes need 18 days to re-establish similar levels of key physiological functions to those seen in the liver. Toxicol Res 2:123–135. https://doi.org/10.1039/C2TX20060K CrossRef

Wrzesinski K, Fey SJ (2018) Metabolic reprogramming and the recovery of physiological functionality in 3D cultures in micro-bioreactors. Bioengineering (Basel) 5:E22. https://doi.org/10.3390/bioengineering5010022 CrossRef

Wrzesinski K, Rogowska-Wrzesinska A, Kanlaya R, Borkowski K, Schwämmle V, Dai J, Joensen KE, Wojdyla K, Carvalho VB, Fey SJ (2014) The cultural divide: exponential growth in classical 2D and metabolic equilibrium in 3D environments. PLoS One 9:e106973. https://doi.org/10.1371/journal.pone.0106973 CrossRefPubMedPubMedCentral

Wu T, Chen ZS, To KKW, Fang X, Wang F, Cheng B, Fu L (2017) Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo. Biochem Pharmacol 124:29–42. https://doi.org/10.1016/j.bcp.2016.10.015 CrossRefPubMed

Xue C, Wang C, Liu Q, Meng Q, Sun H, Huo X, Ma X, Liu Z, Ma X, Peng J, Liu K (2016) Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin. Tumour Biol 37:8587–8597. https://doi.org/10.1007/s13277-015-4478-8 CrossRefPubMed

Yan Y-Y, Wang F, Zhao X-Q, Wang X-K, Chen Y-F, Liu H, Xie Y, Fu L-W (2017) Degradation of P-glycoprotein by pristimerin contributes to overcoming ABCB1-mediated chemotherapeutic drug resistance in vitro. Oncol Rep 37:31–40. https://doi.org/10.3892/or.2016.5230 CrossRefPubMed

Yang X, Feng Y, Gao Y, Shen J, Choy E, Cote G, Harmon D, Zhang Z, Mankin H, Hornicek FJ, Duan Z (2015) NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo. Gynecol Oncol 137:134–142. https://doi.org/10.1016/j.ygyno.2015.02.002 CrossRefPubMed

Yang SD, Zhu WJ, Zhu QL, Chen WL, Ren ZX, Li F, Yuan ZQ, Li JZ, Liu Y, Zhou XF, Liu C, Zhang XN (2017) Binary-copolymer system base on low-density lipoprotein-coupled N-succinyl chitosan lipoic acid micelles for co-delivery MDR1 siRNA and paclitaxel, enhances antitumor effects via reducing drug. J Biomed Mater Res B Appl Biomater 105:1114–1125. https://doi.org/10.1002/jbm.b.33636 CrossRefPubMed

Yhee JY, Song S, Lee SJ, Park SG, Kim KS, Kim MG, Son S, Koo H, Kwon IC, Jeong JH, Jeong SY, Kim SH, Kim K (2015) Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance. J Control Release 198:1–9. https://doi.org/10.1016/j.jconrel.2014.11.019 CrossRefPubMed

Yi H, Liu L, Sheng N, Li P, Pan H, Cai L, Ma Y (2016) Synergistic therapy of doxorubicin and miR-129-5p with self-cross-linked bioreducible polypeptide nanoparticles reverses multidrug resistance in cancer cells. Biomacromolecules 17:1737–1747. https://doi.org/10.1021/acs.biomac.6b00141 CrossRefPubMed

Yura Y (2017) Presage of oncolytic virotherapy for oral cancer with herpes simplex virus. Jpn Dent Sci Rev 53:53–60. https://doi.org/10.1016/j.jdsr.2016.10.001 CrossRefPubMed

Zakaria N, Satar NA, Abu Halim NH, Ngalim SH, Yusoff NM, Lin J, Yahaya BH (2017) Targeting lung cancer stem cells: research and clinical impacts. Front Oncol 7:80. https://doi.org/10.3389/fonc.2017.00080 CrossRefPubMedPubMedCentral

Zampella JG, Rodic N, Yang WR, Huang CR, Welch J, Gnanakkan VP, Cornish TC, Boeke JD, Burns KH (2016) A map of mobile DNA insertions in the NCI-60 human cancer cell panel. Mob DNA 7:20. https://doi.org/10.1186/s13100-016-0078-4 CrossRefPubMedPubMedCentral

Zander SA, Kersbergen A, Van der Burg E, de Water N, Van Tellingen O, Gunnarsdottir S, Jaspers JE, Nygren AO, Jonkers J, Borst P, Rottenberg S (2010) Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. Cancer Res 70:1700–1710. https://doi.org/10.1158/0008-5472.CAN-09-3367 CrossRefPubMed

Zhang L, Yang X, Li Y, Zheng W, Jiang X (2017) Hollow carbon nanospheres as a versatile platform for co-delivery of siRNA and chemotherapeutics. Carbon 121:79–89. https://doi.org/10.1016/j.carbon.2017.05.084 CrossRef

Zhao D, Zhang H, Yang S, He W, Luan Y (2016) Redox-sensitive mPEG-SS-PTX/TPGS mixed micelles: an efficient drug delivery system for overcoming multidrug resistance. Int J Pharm 515:281–292. https://doi.org/10.1016/j.ijpharm.2016.10.029 CrossRefPubMed

Zhou Q, Ye M, Lu Y, Zhang H, Chen Q, Huang S, Su S (2015) Curcumin improves the tumoricidal effect of Mitomycin C by suppressing ABCG2 expression in stem cell-like breast cancer cells. PLoS One 10:e0136694. https://doi.org/10.1371/journal.pone.0136694 CrossRefPubMedPubMedCentral

Zhu Y, Liu C, Armstrong C, Lou W, Sandher A, Gao AC (2015) Antiandrogens inhibit ABCB1 efflux and ATPase activity and reverse docetaxel resistance in advanced prostate cancer. Clin Cancer Res 21:4133–4142. https://doi.org/10.1158/1078-0432.CCR-15-0269 CrossRefPubMedPubMedCentral

Zou W, Sarisozen C, Torchilin VP (2017) The reversal of multidrug resistance in ovarian carcinoma cells by co-application of tariquidar and paclitaxel in transferrin-targeted polymeric micelles. J Drug Target 25:225–234. https://doi.org/10.1080/1061186X2016.1236113 CrossRefPubMed

Springer Medizin

Models used to screen for the treatment of multidrug resistant cancer facilitated by transporter-based efflux

Abstract

Purpose

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2019

RRx-001 protects normal tissues but not tumors via Nrf2 induction and Bcl-2 inhibition

A prognostic score system with lymph node ratio in stage IIIA-N2 NSCLC patients after surgery and adjuvant chemotherapy

FOXP3 immunoregulatory gene variants are independent predictors of human papillomavirus infection and cervical cancer precursor lesions

Prognosis of carcinoma in situ according to the presence of papillary bladder tumors after bacillus Calmette–Guérin immunotherapy